within Pharmacolibrary.Drugs.ATC.R;

model R06AX29
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.61,
    Cl             = 0.00015333333333333334,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0012900000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 15.0,            
    Vdp             = 0.00053,
    k12             = 23.7,
    k21             = 23.7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R06AX29</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Bilastine is a second-generation non-sedating antihistamine used for the symptomatic treatment of allergic rhinitis and urticaria. It selectively antagonizes peripheral H1 receptors and has little to no affinity for central nervous system receptors, causing minimal drowsiness. Bilastine is approved and used in various countries for the relief of allergy symptoms.</p><h4>Pharmacokinetics</h4><p>Single-dose 20 mg oral bilastine in healthy adult volunteers, both sexes, age range 18-55 years.</p><h4>References</h4><ol><li><p>Sádaba, B, et al., &amp; Valiente, R (2013). Oral availability of bilastine. <i>Clinical drug investigation</i> 33(5) 375–381. DOI:<a href=&quot;https://doi.org/10.1007/s40261-013-0076-y&quot;>10.1007/s40261-013-0076-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23529786/&quot;>https://pubmed.ncbi.nlm.nih.gov/23529786</a></p></li><li><p>Ochoa, D, et al., &amp; Fernández, N (2021). Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation. <i>Advances in therapy</i> 38(7) 4070–4081. DOI:<a href=&quot;https://doi.org/10.1007/s12325-021-01801-y&quot;>10.1007/s12325-021-01801-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34125400/&quot;>https://pubmed.ncbi.nlm.nih.gov/34125400</a></p></li><li><p>Majorek-Olechowska, B, et al., &amp; Arranz, P (2024). Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years With Allergic Rhinoconjunctivitis or Urticaria: A Phase 3 Clinical Trial. <i>Journal of investigational allergology &amp; clinical immunology</i> None 0–None. DOI:<a href=&quot;https://doi.org/10.18176/jiaci.1003&quot;>10.18176/jiaci.1003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38725318/&quot;>https://pubmed.ncbi.nlm.nih.gov/38725318</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R06AX29;
